Reviews Rebetol and Intron A Combination Therapy


No reviews yet.

Rebetron Drug Description
REBETRON™
Combination Therapy containing
REBETOL®
(ribavirin, USP) Capsules and
INTRON® A
(interferon alfa-2b, recombinant) Injection

CONTRAINDICATIONS AND WARNINGS
Combination REBETOL/INTRON A therapy is contraindicated in females who are
pregnant and in the male partners of females who are pregnant. Extreme care
must be taken to avoid pregnancy during therapy and for 6 months after completion
of treatment in female patients, and in female partners of male patients who
are taking combination REBETOL/INTRON A therapy. Females of childbearing potential
and males must use two reliable forms of effective contraception during treatment
and during the 6-month posttreatment follow-up period. Significant teratogenic
and/or embryocidal effects have been demonstrated for ribavirin in all animal
species studied. See CONTRAINDICATIONS and WARNINGS.
REBETOL monotherapy is not effective for the treatment of chronic hepatitis
C and should not be used for this indication. See WARNINGS.

Alpha interferons, including INTRON® A, cause or aggravate fatal or life-threatening
neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should
be monitored closely with periodic clinical and laboratory evaluations. Patients
with persistently severe or worsening signs or symptoms of these conditions
should be withdrawn from therapy. In many but not all cases these disorders
resolve after stopping INTRON A therapy. See WARNINGS,
and ADVERSE REACTIONS.

DRUG DESCRIPTION
REBETOL®
REBETOL is Schering Corporation's brand name for ribavirin, a nucleoside analog
with antiviral activity. The chemical name of ribavirin is 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
and has the following structural formula:








Ribavirin is a white, crystalline powder. It is freely soluble in water and
slightly soluble in anhydrous alcohol. The empirical formula is C8H12N4O5
and the molecular weight is 244.21.
REBETOL Capsules consist of a white powder in a white, opaque, gelatin capsule.
Each capsule contains 200 mg ribavirin and the inactive ingredients microcrystalline
cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate.
The capsule shell consists of gelatin, and titanium dioxide. The capsule is
printed with edible blue pharmaceutical ink which is made of shellac, anhydrous
ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, ammonium
hydroxide, and FD&C Blue #2 aluminum lake.
INTRON® A
INTRON A is Schering Corporation's brand name for interferon alfa-2b, recombinant,
a purified, sterile, recombinant interferon product.
Interferon alfa-2b, recombinant has been classified as an alpha interferon
and is a water-soluble protein composed of 165 amino acids with a molecular
weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained
from the bacterial fermentation of a strain of Escherichia coli bearing
a genetically engineered plasmid containing an interferon alfa-2b gene from
human leukocytes. The fermentation is carried out in a defined nutrient medium
containing the antibiotic tetracycline hydrochloride at a concentration of 5
to 10 mg/L; the presence of this antibiotic is not detectable in the final product.

INTRON A Injection is a clear, colorless solution. The 3 million IU vial of
INTRON A Injection contains 3 million IU of interferon alfa-2b, recombinant
per 0.5 mL. The 18 million IU multidose vial of INTRON A Injection contains
a total of 22.8 million IU of interferon alfa-2b, recombinant per 3.8 mL (3
million IU/0.5 mL) in order to provide the delivery of six 0.5 mL doses, each
containing 3 million IU of INTRON A (for a label strength of 18 million IU).
The 18 million IU INTRON A Injection multidose pen contains a total of 22.5
million IU of interferon alfa-2b, recombinant per 1.5 mL (3 million IU/0.2 mL)
in order to provide the delivery of six 0.2-mL doses, each containing 3 million
IU of INTRON A (for a label strength of 18 million IU). Each mL also contains
7.5 mg sodium chloride, 1.8 mg sodium phosphate dibasic, 1.3 mg sodium phosphate
monobasic, 0.1 mg edetate disodium, 0.1 mg polysorbate 80, and 1.5 mg m-cresol
as a preservative.
Based on the specific activity of approximately 2.6 x 108 IU/mg
protein as measured by HPLC assay, the corresponding quantities of interferon
alfa-2b, recombinant in the vials and pen described above are approximately
0.012 mg, 0.088 mg, and 0.087 mg protein, respectively.
Mechanism of Action
Ribavirin/Interferon alfa-2b, recombinant
The mechanism of inhibition of hepatitis C virus (HCV) RNA by combination therapy
with REBETOL and INTRON A has not been established.Last reviewed on RxList: 3/3/2009




Rebetron Drug Description
REBETRON™
Combination Therapy containing
REBETOL®
(ribavirin, USP) Capsules and
INTRON® A
(interferon alfa-2b, recombinant) Injection

CONTRAINDICATIONS AND WARNINGS
Combination REBETOL/INTRON A therapy is contraindicated in females who are
pregnant and in the male partners of females who are pregnant. Extreme care
must be taken to avoid pregnancy during therapy and for 6 months after completion
of treatment in female patients, and in female partners of male patients who
are taking combination REBETOL/INTRON A therapy. Females of childbearing potential
and males must use two reliable forms of effective contraception during treatment
and during the 6-month posttreatment follow-up period. Significant teratogenic
and/or embryocidal effects have been demonstrated for ribavirin in all animal
species studied. See CONTRAINDICATIONS and WARNINGS.
REBETOL monotherapy is not effective for the treatment of chronic hepatitis
C and should not be used for this indication. See WARNINGS.

Alpha interferons, including INTRON® A, cause or aggravate fatal or life-threatening
neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should
be monitored closely with periodic clinical and laboratory evaluations. Patients
with persistently severe or worsening signs or symptoms of these conditions
should be withdrawn from therapy. In many but not all cases these disorders
resolve after stopping INTRON A therapy. See WARNINGS,
and ADVERSE REACTIONS.

DRUG DESCRIPTION
REBETOL®
REBETOL is Schering Corporation's brand name for ribavirin, a nucleoside analog
with antiviral activity. The chemical name of ribavirin is 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
and has the following structural formula:








Ribavirin is a white, crystalline powder. It is freely soluble in water and
slightly soluble in anhydrous alcohol. The empirical formula is C8H12N4O5
and the molecular weight is 244.21.
REBETOL Capsules consist of a white powder in a white, opaque, gelatin capsule.
Each capsule contains 200 mg ribavirin and the inactive ingredients microcrystalline
cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate.
The capsule shell consists of gelatin, and titanium dioxide. The capsule is
printed with edible blue pharmaceutical ink which is made of shellac, anhydrous
ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, ammonium
hydroxide, and FD&C Blue #2 aluminum lake.
INTRON® A
INTRON A is Schering Corporation's brand name for interferon alfa-2b, recombinant,
a purified, sterile, recombinant interferon product.
Interferon alfa-2b, recombinant has been classified as an alpha interferon
and is a water-soluble protein composed of 165 amino acids with a molecular
weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained
from the bacterial fermentation of a strain of Escherichia coli bearing
a genetically engineered plasmid containing an interferon alfa-2b gene from
human leukocytes. The fermentation is carried out in a defined nutrient medium
containing the antibiotic tetracycline hydrochloride at a concentration of 5
to 10 mg/L; the presence of this antibiotic is not detectable in the final product.

INTRON A Injection is a clear, colorless solution. The 3 million IU vial of
INTRON A Injection contains 3 million IU of interferon alfa-2b, recombinant
per 0.5 mL. The 18 million IU multidose vial of INTRON A Injection contains
a total of 22.8 million IU of interferon alfa-2b, recombinant per 3.8 mL (3
million IU/0.5 mL) in order to provide the delivery of six 0.5 mL doses, each
containing 3 million IU of INTRON A (for a label strength of 18 million IU).
The 18 million IU INTRON A Injection multidose pen contains a total of 22.5
million IU of interferon alfa-2b, recombinant per 1.5 mL (3 million IU/0.2 mL)
in order to provide the delivery of six 0.2-mL doses, each containing 3 million
IU of INTRON A (for a label strength of 18 million IU). Each mL also contains
7.5 mg sodium chloride, 1.8 mg sodium phosphate dibasic, 1.3 mg sodium phosphate
monobasic, 0.1 mg edetate disodium, 0.1 mg polysorbate 80, and 1.5 mg m-cresol
as a preservative.
Based on the specific activity of approximately 2.6 x 108 IU/mg
protein as measured by HPLC assay, the corresponding quantities of interferon
alfa-2b, recombinant in the vials and pen described above are approximately
0.012 mg, 0.088 mg, and 0.087 mg protein, respectively.
Mechanism of Action
Ribavirin/Interferon alfa-2b, recombinant
The mechanism of inhibition of hepatitis C virus (HCV) RNA by combination therapy
with REBETOL and INTRON A has not been established.Last reviewed on RxList: 3/3/2009




Rebetron Drug Description
REBETRON™
Combination Therapy containing
REBETOL®
(ribavirin, USP) Capsules and
INTRON® A
(interferon alfa-2b, recombinant) Injection

CONTRAINDICATIONS AND WARNINGS
Combination REBETOL/INTRON A therapy is contraindicated in females who are
pregnant and in the male partners of females who are pregnant. Extreme care
must be taken to avoid pregnancy during therapy and for 6 months after completion
of treatment in female patients, and in female partners of male patients who
are taking combination REBETOL/INTRON A therapy. Females of childbearing potential
and males must use two reliable forms of effective contraception during treatment
and during the 6-month posttreatment follow-up period. Significant teratogenic
and/or embryocidal effects have been demonstrated for ribavirin in all animal
species studied. See CONTRAINDICATIONS and WARNINGS.
REBETOL monotherapy is not effective for the treatment of chronic hepatitis
C and should not be used for this indication. See WARNINGS.

Alpha interferons, including INTRON® A, cause or aggravate fatal or life-threatening
neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should
be monitored closely with periodic clinical and laboratory evaluations. Patients
with persistently severe or worsening signs or symptoms of these conditions
should be withdrawn from therapy. In many but not all cases these disorders
resolve after stopping INTRON A therapy. See WARNINGS,
and ADVERSE REACTIONS.

DRUG DESCRIPTION
REBETOL®
REBETOL is Schering Corporation's brand name for ribavirin, a nucleoside analog
with antiviral activity. The chemical name of ribavirin is 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
and has the following structural formula:








Ribavirin is a white, crystalline powder. It is freely soluble in water and
slightly soluble in anhydrous alcohol. The empirical formula is C8H12N4O5
and the molecular weight is 244.21.
REBETOL Capsules consist of a white powder in a white, opaque, gelatin capsule.
Each capsule contains 200 mg ribavirin and the inactive ingredients microcrystalline
cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate.
The capsule shell consists of gelatin, and titanium dioxide. The capsule is
printed with edible blue pharmaceutical ink which is made of shellac, anhydrous
ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, ammonium
hydroxide, and FD&C Blue #2 aluminum lake.
INTRON® A
INTRON A is Schering Corporation's brand name for interferon alfa-2b, recombinant,
a purified, sterile, recombinant interferon product.
Interferon alfa-2b, recombinant has been classified as an alpha interferon
and is a water-soluble protein composed of 165 amino acids with a molecular
weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained
from the bacterial fermentation of a strain of Escherichia coli bearing
a genetically engineered plasmid containing an interferon alfa-2b gene from
human leukocytes. The fermentation is carried out in a defined nutrient medium
containing the antibiotic tetracycline hydrochloride at a concentration of 5
to 10 mg/L; the presence of this antibiotic is not detectable in the final product.

INTRON A Injection is a clear, colorless solution. The 3 million IU vial of
INTRON A Injection contains 3 million IU of interferon alfa-2b, recombinant
per 0.5 mL. The 18 million IU multidose vial of INTRON A Injection contains
a total of 22.8 million IU of interferon alfa-2b, recombinant per 3.8 mL (3
million IU/0.5 mL) in order to provide the delivery of six 0.5 mL doses, each
containing 3 million IU of INTRON A (for a label strength of 18 million IU).
The 18 million IU INTRON A Injection multidose pen contains a total of 22.5
million IU of interferon alfa-2b, recombinant per 1.5 mL (3 million IU/0.2 mL)
in order to provide the delivery of six 0.2-mL doses, each containing 3 million
IU of INTRON A (for a label strength of 18 million IU). Each mL also contains
7.5 mg sodium chloride, 1.8 mg sodium phosphate dibasic, 1.3 mg sodium phosphate
monobasic, 0.1 mg edetate disodium, 0.1 mg polysorbate 80, and 1.5 mg m-cresol
as a preservative.
Based on the specific activity of approximately 2.6 x 108 IU/mg
protein as measured by HPLC assay, the corresponding quantities of interferon
alfa-2b, recombinant in the vials and pen described above are approximately
0.012 mg, 0.088 mg, and 0.087 mg protein, respectively.
Mechanism of Action
Ribavirin/Interferon alfa-2b, recombinant
The mechanism of inhibition of hepatitis C virus (HCV) RNA by combination therapy
with REBETOL and INTRON A has not been established.Last reviewed on RxList: 3/3/2009




Rebetron Drug Description
REBETRON™
Combination Therapy containing
REBETOL®
(ribavirin, USP) Capsules and
INTRON® A
(interferon alfa-2b, recombinant) Injection

CONTRAINDICATIONS AND WARNINGS
Combination REBETOL/INTRON A therapy is contraindicated in females who are
pregnant and in the male partners of females who are pregnant. Extreme care
must be taken to avoid pregnancy during therapy and for 6 months after completion
of treatment in female patients, and in female partners of male patients who
are taking combination REBETOL/INTRON A therapy. Females of childbearing potential
and males must use two reliable forms of effective contraception during treatment
and during the 6-month posttreatment follow-up period. Significant teratogenic
and/or embryocidal effects have been demonstrated for ribavirin in all animal
species studied. See CONTRAINDICATIONS and WARNINGS.
REBETOL monotherapy is not effective for the treatment of chronic hepatitis
C and should not be used for this indication. See WARNINGS.

Alpha interferons, including INTRON® A, cause or aggravate fatal or life-threatening
neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should
be monitored closely with periodic clinical and laboratory evaluations. Patients
with persistently severe or worsening signs or symptoms of these conditions
should be withdrawn from therapy. In many but not all cases these disorders
resolve after stopping INTRON A therapy. See WARNINGS,
and ADVERSE REACTIONS.

DRUG DESCRIPTION
REBETOL®
REBETOL is Schering Corporation's brand name for ribavirin, a nucleoside analog
with antiviral activity. The chemical name of ribavirin is 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
and has the following structural formula:








Ribavirin is a white, crystalline powder. It is freely soluble in water and
slightly soluble in anhydrous alcohol. The empirical formula is C8H12N4O5
and the molecular weight is 244.21.
REBETOL Capsules consist of a white powder in a white, opaque, gelatin capsule.
Each capsule contains 200 mg ribavirin and the inactive ingredients microcrystalline
cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate.
The capsule shell consists of gelatin, and titanium dioxide. The capsule is
printed with edible blue pharmaceutical ink which is made of shellac, anhydrous
ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, ammonium
hydroxide, and FD&C Blue #2 aluminum lake.
INTRON® A
INTRON A is Schering Corporation's brand name for interferon alfa-2b, recombinant,
a purified, sterile, recombinant interferon product.
Interferon alfa-2b, recombinant has been classified as an alpha interferon
and is a water-soluble protein composed of 165 amino acids with a molecular
weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained
from the bacterial fermentation of a strain of Escherichia coli bearing
a genetically engineered plasmid containing an interferon alfa-2b gene from
human leukocytes. The fermentation is carried out in a defined nutrient medium
containing the antibiotic tetracycline hydrochloride at a concentration of 5
to 10 mg/L; the presence of this antibiotic is not detectable in the final product.

INTRON A Injection is a clear, colorless solution. The 3 million IU vial of
INTRON A Injection contains 3 million IU of interferon alfa-2b, recombinant
per 0.5 mL. The 18 million IU multidose vial of INTRON A Injection contains
a total of 22.8 million IU of interferon alfa-2b, recombinant per 3.8 mL (3
million IU/0.5 mL) in order to provide the delivery of six 0.5 mL doses, each
containing 3 million IU of INTRON A (for a label strength of 18 million IU).
The 18 million IU INTRON A Injection multidose pen contains a total of 22.5
million IU of interferon alfa-2b, recombinant per 1.5 mL (3 million IU/0.2 mL)
in order to provide the delivery of six 0.2-mL doses, each containing 3 million
IU of INTRON A (for a label strength of 18 million IU). Each mL also contains
7.5 mg sodium chloride, 1.8 mg sodium phosphate dibasic, 1.3 mg sodium phosphate
monobasic, 0.1 mg edetate disodium, 0.1 mg polysorbate 80, and 1.5 mg m-cresol
as a preservative.
Based on the specific activity of approximately 2.6 x 108 IU/mg
protein as measured by HPLC assay, the corresponding quantities of interferon
alfa-2b, recombinant in the vials and pen described above are approximately
0.012 mg, 0.088 mg, and 0.087 mg protein, respectively.
Mechanism of Action
Ribavirin/Interferon alfa-2b, recombinant
The mechanism of inhibition of hepatitis C virus (HCV) RNA by combination therapy
with REBETOL and INTRON A has not been established.Last reviewed on RxList: 3/3/2009




Rebetron Drug Description
REBETRON™
Combination Therapy containing
REBETOL®
(ribavirin, USP) Capsules and
INTRON® A
(interferon alfa-2b, recombinant) Injection

CONTRAINDICATIONS AND WARNINGS
Combination REBETOL/INTRON A therapy is contraindicated in females who are
pregnant and in the male partners of females who are pregnant. Extreme care
must be taken to avoid pregnancy during therapy and for 6 months after completion
of treatment in female patients, and in female partners of male patients who
are taking combination REBETOL/INTRON A therapy. Females of childbearing potential
and males must use two reliable forms of effective contraception during treatment
and during the 6-month posttreatment follow-up period. Significant teratogenic
and/or embryocidal effects have been demonstrated for ribavirin in all animal
species studied. See CONTRAINDICATIONS and WARNINGS.
REBETOL monotherapy is not effective for the treatment of chronic hepatitis
C and should not be used for this indication. See WARNINGS.

Alpha interferons, including INTRON® A, cause or aggravate fatal or life-threatening
neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should
be monitored closely with periodic clinical and laboratory evaluations. Patients
with persistently severe or worsening signs or symptoms of these conditions
should be withdrawn from therapy. In many but not all cases these disorders
resolve after stopping INTRON A therapy. See WARNINGS,
and ADVERSE REACTIONS.

DRUG DESCRIPTION
REBETOL®
REBETOL is Schering Corporation's brand name for ribavirin, a nucleoside analog
with antiviral activity. The chemical name of ribavirin is 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
and has the following structural formula:








Ribavirin is a white, crystalline powder. It is freely soluble in water and
slightly soluble in anhydrous alcohol. The empirical formula is C8H12N4O5
and the molecular weight is 244.21.
REBETOL Capsules consist of a white powder in a white, opaque, gelatin capsule.
Each capsule contains 200 mg ribavirin and the inactive ingredients microcrystalline
cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate.
The capsule shell consists of gelatin, and titanium dioxide. The capsule is
printed with edible blue pharmaceutical ink which is made of shellac, anhydrous
ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, ammonium
hydroxide, and FD&C Blue #2 aluminum lake.
INTRON® A
INTRON A is Schering Corporation's brand name for interferon alfa-2b, recombinant,
a purified, sterile, recombinant interferon product.
Interferon alfa-2b, recombinant has been classified as an alpha interferon
and is a water-soluble protein composed of 165 amino acids with a molecular
weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained
from the bacterial fermentation of a strain of Escherichia coli bearing
a genetically engineered plasmid containing an interferon alfa-2b gene from
human leukocytes. The fermentation is carried out in a defined nutrient medium
containing the antibiotic tetracycline hydrochloride at a concentration of 5
to 10 mg/L; the presence of this antibiotic is not detectable in the final product.

INTRON A Injection is a clear, colorless solution. The 3 million IU vial of
INTRON A Injection contains 3 million IU of interferon alfa-2b, recombinant
per 0.5 mL. The 18 million IU multidose vial of INTRON A Injection contains
a total of 22.8 million IU of interferon alfa-2b, recombinant per 3.8 mL (3
million IU/0.5 mL) in order to provide the delivery of six 0.5 mL doses, each
containing 3 million IU of INTRON A (for a label strength of 18 million IU).
The 18 million IU INTRON A Injection multidose pen contains a total of 22.5
million IU of interferon alfa-2b, recombinant per 1.5 mL (3 million IU/0.2 mL)
in order to provide the delivery of six 0.2-mL doses, each containing 3 million
IU of INTRON A (for a label strength of 18 million IU). Each mL also contains
7.5 mg sodium chloride, 1.8 mg sodium phosphate dibasic, 1.3 mg sodium phosphate
monobasic, 0.1 mg edetate disodium, 0.1 mg polysorbate 80, and 1.5 mg m-cresol
as a preservative.
Based on the specific activity of approximately 2.6 x 108 IU/mg
protein as measured by HPLC assay, the corresponding quantities of interferon
alfa-2b, recombinant in the vials and pen described above are approximately
0.012 mg, 0.088 mg, and 0.087 mg protein, respectively.
Mechanism of Action
Ribavirin/Interferon alfa-2b, recombinant
The mechanism of inhibition of hepatitis C virus (HCV) RNA by combination therapy
with REBETOL and INTRON A has not been established.Last reviewed on RxList: 3/3/2009





Other reviews about Rebetol and Intron A Combination Therapy on wordpress

Side effects whilst on tx
  by Lynne
I have been asked what side effects there are from the treatment a couple of times in the last few days, so I thought it would be a […]


Hepatitis C
  by livertransplantinindia
IntroductionHepatitis C is a virus that often silently attacks your liver. Most people infected with the hepatitis C virus (HCV) have no symptoms at all. In fact, most […]


Next Generation Hep C Drugs -- Vertex v. Schering -- Who's Ahead? And, whose drug sports "the most rashes"?
  by condor
It is hard to read Schering-Plough's press release of this morning as anything but a "Me, too!" faux-clarion-call. "How so?", you might ask. Well. . . . the […]


Schering-Plough Announces FDA Approval Of PEGINTRON(TM) And REBETOL(R) Combination Therapy For Treating Pediatric Hepatitis C
  by yestelli
First and only approved peginterferon in combination with ribavirin for previously untreated children with chronic hepatitis C addresses unmet medical need Schering-Plough Corporation (NYSE: SGP) today announced that […]


Schering-Plough Announces FDA Approval Of PEGINTRON(TM) And REBETOL(R) Combination Therapy For Treating Pediatric Hepatitis C
  by healtherm2
First and only approved peginterferon in combination with ribavirin for previously untreated children with chronic hepatitis C addresses unmet medical need Schering-Plough Corporation (NYSE: SGP) today announced that […]


Forex Start currency exchange
  by allyngrandallw
Through its own biopharmaceutical research african hoodia cactus and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. About Schering-Plough Schering-Plough is […]


Weight Loss Weight loss herbs
  by sibellebashleyr
In many, but not diet pills you can buy with ephrtha all cases, these disorders resolve after stopping PEGINTRON and/or INTRON A therapy. Avoid Pregnancy phentermine diet pills […]


Merck - Schering-Plough
  by El Horror
About - Schering-Plough = Merger of Schering Corporation and Plough Inc. in 1971. - 2009: Merger of Merck & Co. Inc. (68%) and Schering-Plough (32%). 41.1 billion dollar deal by […]


History of Hep C
  by hephopdeluxe
A Brief History of Hepatitis C Alan Franciscus, Editor-in-Chief The management and care of hepatitis C has come a […]


Nicholas gave the promise; he had fe
  by qpauymcuuh
She had made a desk for the two children by means of the ironingboard, which was a long and wide board, made very smooth on both sides. 4:20 […]



Other reviews about Rebetol and Intron A Combination Therapy on web:

Learn about the prescription medication Rebetron (Rebetol and Intron A Combination Therapy), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient ... Rebetron (Rebetol and Intron A Combination Therapy) Drug ...


Rebetol may be taken with or without food when used in combination therapy with Intron A, but whichever way you choose, do it consistently. When Rebetol is used in combination ... Rebetol patient advice including side effects


Phase III Results of INTRON A(R) and REBETOL(TM) Combination Therapy in Treatment-Naive Hepatitis C Patients Announced. Monday May 18, 8:52 am Eastern Time Hepatitis C,Phase III Results of INTRON A(R) and REBETOL(TM ...


FDA Approves PEG-Intron/Rebetol Combination Therapy For Chronic Hepatitis C KENILWORTH, N.J. -- August 8, 2001 -- Schering-Plough Corporation today announced that the U.S. Food and ... FDA Approves PEG-Intron/Rebetol Combination Therapy For Chronic ...


There have been reports of interferon, including INTRON A (interferon alfa-2b, recombinant), exacerbating pre-existing psoriasis; therefore, combination REBETOL/INTRON A therapy ... Intron A - Rebetol (Ribavirin, Interferon Alfa-2b, Recombinant ...


SAN FRANCISCO, Nov. ... PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates Consistently High Response Rates Across Patient Weight Groups in 'Real-Life' Treatment Setting PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates ...


Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination Rebetol/Intron A therapy. Combination Rebetol/Intron A ... Rebetol


Rebetol has been approved in the United States since 1998 as part of a single-package combination therapy (known as Rebetron) that includes Rebetol capsules and Intron A injection. Rebetol (ribavirin) - Drug information from MediLexicon


INDICATIONS Adult Use. REBETOL (ribavirin, USP) Capsules and Oral Solution are indicated in combination with INTRON A (interferon alfa-2b, recombinant) for Injection Antiviral Therapy Home


Combination Therapy Pegasys + Copegus (peginterferon alfa-2a ... Articles on Intron A + Rebetol FDA-Approved Combination Therapy





Featured Reviews

Reviews Clotrimazole Vaginal Cream

Gyne-Lotrimin Drug Description DRUG DESCRIPTION What are the possible side effects of clotrimazole vaginal (Femcare, Gyne-Lotrimin, Mycelex-G)? Stop using clotrimazole vaginal and seek emergency medical attention if you experience...
Read More  |  Review This
Reviews Cetirizine

Zyrtec Drug Description ZYRTEC® (cetirizine hydrochloride) Tablets, Chewable Tablets and Syrup Now available Over-The-Counter (OTC); No prescription needed. DRUG DESCRIPTION What are the possible side effects of cetirizine...
Read More  |  Review This
Reviews Sandimmune

Sandimmune Drug Description Sandimmune® (cyclosporine, USP) Soft Gelatin Capsules Sandimmune® (cyclosporine, USP) Oral Solution Sandimmune® (cyclosporine, USP) Injection WARNING Only physicians experienced in immunosuppressi...
Read More  |  Review This
Reviews Pancrecarb

Pancrecarb Drug Description PANCRECARB® (pancrelipase) Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres. DRUG DESCRIPTION What are the possible side effects of pancrelipase? Get emergency medical help if...
Read More  |  Review This
Reviews Ibritumomab Tiuxetan

Zevalin Drug Description ZEVALIN® (ibritumomab tiuxetan) Injection for Intravenous Use WARNING SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS, and SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS Serious Infusion Reactions:...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....